- Trial Phase
- Approved / Discontinued
- Time to Market
- PERSERIS was already FDA-approved (July 2018) and marketed until its discontinuation. It is no longer available for prescription as of May 31, 2026.
- Why 1/10
- PERSERIS has been fully discontinued (final availability ended May 31, 2026) with no remaining regulatory or clinical catalysts. As a zero-revenue legacy product, it drives no share-price movement for Indivior, resulting in the lowest impact score.
PERSERIS is a fully discontinued product with zero revenue contribution and no remaining catalysts. The stock's value story now rests entirely on SUBLOCADE's commercial trajectory and the pending Supernus merger (expected Q4 2026); PERSERIS is irrelevant to future price action.
Price Chart
Executive Summary
PERSERIS (risperidone extended-release injectable suspension) is a once-monthly injectable atypical antipsychotic that was FDA-approved in July 2018 for the treatment of schizophrenia in adults. Developed and marketed by Indivior Pharmaceuticals (NASDAQ: INDV), the drug faced intense competition from established long-acting injectable antipsychotics and growing payer management pressure. In July 2024, Indivior announced it would discontinue all sales and marketing activities for PERSERIS, cutting 130 jobs and taking a financial hit that sent shares down ~34-40%. The drug's full commercial availability ended on May 31, 2026, and it now generates zero revenue for the company. The discontinuation was not related to safety or efficacy concerns. Indivior has since refocused entirely on its opioid use disorder drug SUBLOCADE, which posted record quarterly revenue in Q3 2026, and is in the process of merging with Supernus Pharmaceuticals in an all-stock deal expected to close in Q4 2026.
How It Works
PERSERIS is a once-monthly injection of risperidone, an atypical antipsychotic medication. It is injected under the skin (subcutaneously) and slowly releases the drug over the course of a month. Risperidone works by blocking dopamine and serotonin receptors in the brain, which helps reduce the hallucinations, delusions, and disorganized thinking associated with schizophrenia.
Trial Status
PERSERIS completed its clinical development program (including a Phase 3 double-blind placebo-controlled trial and a 52-week open-label study) and received FDA approval on July 27, 2018. Indivior ceased sales and marketing activities on July 9, 2024, and fully discontinued product availability on May 31, 2026.
The Two-Sided Case
Upcoming Catalysts
- None. PERSERIS has been fully discontinued with no remaining regulatory, clinical, or commercial catalysts.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Indivior Pharmaceuticals Inc. PRESS-RELEASE INDV ·Originating report